65,437 trials
Diabetes Mellitus, Type 1
Primary: Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Missed Meal Bolus — 1.79; 2.55 Hours — p=0.1450
Children · Lacerations · Procedures
Primary: Statistical Difference in Pain Scores in Children During Laceration Repair Between Study and Placebo Group — 5; 7 units on a scale — p=0.05
Hepatitis B
Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…
COVID-19 · Sars-CoV2
Primary: Mechanical Ventilation or Death Endpoint — 2; 0 Participants
Drug Effect · Rib Fractures · Rib Trauma
Primary: Daily Sequential Clinical Assessment of Respiratory Function (SCARF) Score — 2; 2 score on a scale — p=0.12
Acute Myeloid Leukemia (Relapsed/Refractory)
Primary: Number of Participants With CR/CRi = Overall Reponse Rate — 15; 6 Participants
Surgical Wound · Shoulder Arthritis · Surgical Incision
Primary: Comparison of the Total Cost of Wound Closure When Using Dermabond PRINEO Versus the Surgeon's Control. — 627.83; 304.75; 568.53; 420.77 Dollars
Cerebral Palsy (CP)
Primary: Change in Baseline Gait Profile Score (GPS) at 3 Months-individual Lower Extremity Joint Kinematics — 0.41; -0.48 units on a scale — p=0.36
Multiple System Atrophy
Primary: TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) — 52; 28; 49; 21 events
Stroke
Primary: Percentage Change in Step Length Asymmetry — 11.6 % change in asymmetry
Gastroparesis
Primary: Patient Ability to Prepare and Administer the 13C-Spirulina GEBT, Under the Supervision of a Telehealth Professional, According to Instructions — 34; 34; 34; 34…
Asthma
Primary: Asthma Control Test (ACT) — 21.8; 19.9 units on a scale
Ischemic Stroke · Atherosclerosis
Primary: The Composite of Cerebral Ischemic Stroke and Transient Ischemic Attack — 0; 0; 0; 1 Participants — p=0.462
Colorectal Neoplasm
Primary: Number of Participants With Best Objective Response Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With…
IgG4-related Disease
Primary: Treatment Response — 3 Participants